The Full Wiki

Erlotinib: Quiz

Advertisements
  
  

Question 1: It binds in a reversible fashion to the ________ (ATP) binding site of the receptor.
Adenosine monophosphateCytidine triphosphateAdenosine triphosphateAdenosine diphosphate

Question 2: It is marketed in the United States by ________ and OSI Pharmaceuticals and elsewhere by Roche.
BevacizumabGenentechArthur Riggs (geneticist)Eli Lilly and Company

Question 3: Tarceva is currently (2009) available for free in Scotland but not in ________, as the National Institute for Health and Clinical Excellence (NICE) found it was not "an effective use of NHS resources".
British peopleEnglandWalesUnited Kingdom

Question 4: JAK2V617F is a mutant of tyrosine kinase ________, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia.
Epidermal growth factor receptorCD117Janus kinase 1Janus kinase 2

Question 5: Rarely, interstitial pneumonitis, which is characterized by cough and increased ________.
OrthopneaHemoptysisShortness of breathPleurisy

Question 6: Some of the cases, including ones which resulted in death, were suggestive of ________/toxic epidermal necrolysis.
Stevens–Johnson syndromeUrticariaPsoriasisSystemic lupus erythematosus

Question 7: In November 2005, the U.S. Food and Drug Administration (FDA) approved the use of erlotinib in combination with gemcitabine for treatment of locally advanced, unresectable, or metastatic ________.
Islet cell carcinomaICD-10 Chapter II: NeoplasmsCholangiocarcinomaPancreatic cancer

Question 8: bcr-abl (Dasatinib, ________, Nilotinib)
ImatinibAripiprazoleClozapineSildenafil

Question 9: Erlotinib hydrochloride (Tarceva) is a drug used to treat non-small cell ________, pancreatic cancer and several other types of cancer.
MesotheliomaLung cancerSolitary pulmonary noduleNon-small cell lung carcinoma

Question 10: It was approved for the treatment of locally advanced or metastatic non-small cell lung cancer that has failed at least one prior ________ regimen.
Cancer immunotherapyChemotherapyATC code LAntineoplastic







Advertisements









Got something to say? Make a comment.
Your name
Your email address
Message